Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.

Keiko TanimuraJunji UchinoHideharu KimuraOsamu HiranumaYusuke ChiharaShigeru TanzawaChieko TakumiToshiyuki KitaKoji InoueKoichi MinatoShinnosuke TakemotoAkira NakaoKenichi YoshimuraKoichi Takayama

Published in: The oncologist (2023)

No clinical concerns were identified with DOC/RAM for NSCLC with brain metastases in this study. Further investigation with a larger sample size is needed to determine the tolerability and safety of these populations (Trial Identifiers: University Hospital Medical Information Network in Japan [UMIN000024551] and Japan Registry of Clinical Trials [jRCTs071180048]).

Keyphrases

brain metastases
open label
clinical trial
small cell lung cancer
phase ii
phase iii
study protocol
double blind
phase ii study
placebo controlled
healthcare
health information
randomized controlled trial
radiation therapy